Veterinary medicine is typically less impeded by FDA regulatory costs than human medicine. A cynic would note that the publicity-related incentives operating on FDA staff and leadership are quite different in these two cases, with a great deal more attention given by the media to matters regarding human medicine. With the relative costs being what they are, a number of entrepreneurs in the longevity industry chose to work towards veterinary therapies targeting mechanisms of aging. One of those companies, Loyal, here reports on progress towards the FDA essentially agreeing to a regulatory framework for therapies targeting aging rather than specific diseases. On the human side of the house, you might recall that the primary analogous effort is the <a href="https://www.fightaging.org/archives/2022/08/discussing-the-state-of-…
Progressing Towards Regulatory Approval of Veterinary Therapies Targeting Aging
Veterinary medicine is typically less impeded by FDA regulatory costs than human medicine. A cynic would note that the publicity-related incentives operating on FDA staff and leadership are quite different in these two cases, with a great deal more attention given by the media to matters regarding human medicine. With the relative costs being what they are, a number of entrepreneurs in the longevity industry chose to work towards veterinary therapies targeting mechanisms of aging. One of those companies, Loyal, here reports on progress towards the FDA essentially agreeing to a regulatory framework for therapies targeting aging rather than specific diseases. On the human side of the house, you might recall that the primary analogous effort is the <a href="https://www.fightaging.org/archives/2022/08/discussing-the-state-of-…